International equities, as represented by the iShares MSCI EAFE ETF (ticker: EFA), have delivered a standout performance. This fund provides diversified exposure to developed markets outside the United States and Canada. In a notable shift, the MSCI EAFE index surged 31.2% throughout 2025, significantly outpacing the S&P 500’s 17.9% gain. This raises a pivotal question for investors: can this divergence from U.S. market performance be sustained?
Key Fund Metrics
* Assets Under Management: $72.92 billion
* Expense Ratio: 0.32%
* Replication Method & Distribution: Physical replication with semi-annual dividends
* Major Country Allocations: Japan (22.16%), United Kingdom (14.63%), France (10.84%)
* Performance Data (Mid-January 2026): 1-year return of +37.53%; year-to-date return of +2.81%
Composition and Sector Exposure
The ETF’s portfolio contains more than 700 large- and mid-capitalization stocks. Its top ten holdings, which include industry leaders like ASML, Roche, and AstraZeneca, constitute approximately 13.3% of total assets, preventing any single security from dominating. The fund’s sector allocation reveals a significant tilt toward Financials, which account for 24.9% of the portfolio. Industrials (19.6%) and Health Care (11.4%) represent the next largest sector weights. This broad diversification across both nations and industries is designed to mitigate country-specific economic risks.
Trading Dynamics and Recent Returns
EFA demonstrates high liquidity, with average daily volume reaching 15–20 million shares in early January and a typical bid-ask spread of around 0.01%. As of January 15, 2026, the ETF traded at a modest 0.03% premium to its Net Asset Value (NAV) of $99.17. Its one-year median premium has historically been near 0.06%, indicating efficient tracking of the underlying index. The fund has also shown strong recent momentum, posting gains of 8.78% over three months and 5.41% over one month.
Should investors sell immediately? Or is it worth buying iShares MSCI EAFE ETF?
Competitive Landscape and Forward Drivers
Investors evaluating EFA must consider lower-cost alternatives in the same category. Competing funds include the iShares Core MSCI EAFE ETF (IEFA) with a 0.07% expense ratio and roughly $169.9 billion in AUM, and the Vanguard FTSE Developed Markets ETF (VEA), which charges 0.03% and manages approximately $200.8 billion. While EFA boasts a long track record and excellent liquidity, its higher fee structure presents a headwind to net returns compared to these core, index-tracking products.
Several concrete factors will influence the fund’s trajectory in the coming months. The semi-annual index rebalancing, with the next scheduled for May, is a key event. Macroeconomic conditions also play a crucial role, notably the U.S. dollar’s 9.4% depreciation in 2025, which provided a tailwind for foreign asset returns. Thematic trends such as widespread AI adoption and rising defense budgets may continue to support technology and industrial constituents. Furthermore, an anticipated easing of restrictive U.S. monetary policy in 2026 is expected to influence currency dynamics, a critical component of returns for U.S.-based investors in international funds like EFA.
Until the May rebalancing, currency fluctuations and the performance of core sectors—including semiconductor equipment, pharmaceuticals, and industrials—will likely dictate the ETF’s short- to medium-term direction.
Ad
iShares MSCI EAFE ETF Stock: Buy or Sell?! New iShares MSCI EAFE ETF Analysis from January 16 delivers the answer:
The latest iShares MSCI EAFE ETF figures speak for themselves: Urgent action needed for iShares MSCI EAFE ETF investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 16.
iShares MSCI EAFE ETF: Buy or sell? Read more here...











